A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Trial Profile

A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Tenofovir (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 26 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 27 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 26 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top